Literature DB >> 29475923

Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis.

Szymon Darocha1, Michał Wilk1,2, Anna Walaszkowska-Czyż2, Jarosław Kępski1, Rafał Mańczak1, Marcin Kurzyna1, Adam Torbicki1, Sebastian Szmit3.   

Abstract

BACKGROUND: Pericardial effusion is associated with high mortality in oncology. The etiology of infectious pericarditis and iatrogenic effects of previous radio-/chemotherapy may be always suspected, especially when a subsequent episode is observed. PATIENTS AND METHODS: The study included 17 hemodynamically-unstable patients with cancer due to recurrent pericardial bloody effusion after previous pericardiocentesis and analyzed survival determinants after intrapericardial chemotherapy with cisplatin.
RESULTS: The mortality rate was not significantly associated with the level of N-terminal pro-B type natriuretic peptide, low hemoglobin (<12 g/dl), elevated white blood cell account (>104/μl), large volume (>1500 ml) and long duration (>8 days) of pericardial drainage, cardiac arrhythmias, positive culture test results nor fever occurring during cisplatin administration. Subsequent systemic anticancer therapy was the strongest factor determining a longer survival (hazard ratio(HR)=0.31, 95% confidence interval(CI)=0.11-0.9; p=0.03).
CONCLUSION: Efficacy of rescue intrapericardial chemotherapy with cisplatin is independent of parameters of hemodynamic instability and levels of inflammatory markers in recurrent pericardial effusion. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Recurrent pericardial effusion; cardio-oncology; cisplatin; pericardiocentesis

Mesh:

Substances:

Year:  2018        PMID: 29475923      PMCID: PMC5905208          DOI: 10.21873/invivo.11248

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  36 in total

Review 1.  Controversial issues in the management of pericardial diseases.

Authors:  Massimo Imazio; David H Spodick; Antonio Brucato; Rita Trinchero; Yehuda Adler
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

2.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

Review 3.  Triage and management of pericardial effusion.

Authors:  Massimo Imazio; Bongani M Mayosi; Antonio Brucato; Gal Markel; Rita Trinchero; David H Spodick; Yehuda Adler
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2010-12       Impact factor: 2.160

4.  Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer.

Authors:  W Z Tomkowski; S Filipecki
Journal:  Lung Cancer       Date:  1997-03       Impact factor: 5.705

5.  Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa).

Authors:  T S Bishiniotis; S Antoniadou; G Katseas; D Mouratidou; A G Litos; N Balamoutsos
Journal:  Am J Cardiol       Date:  2000-08-01       Impact factor: 2.778

6.  Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade.

Authors:  Witold Zbyszek Tomkowski; Joanna Wiśniewska; Monika Szturmowicz; Paweł Kuca; Janusz Burakowski; Jarosław Kober; Anna Fijałkowska
Journal:  Support Care Cancer       Date:  2003-09-23       Impact factor: 3.603

7.  Indicators of poor prognosis of acute pericarditis.

Authors:  Massimo Imazio; Enrico Cecchi; Brunella Demichelis; Salvatore Ierna; Daniela Demarie; Aldo Ghisio; Franco Pomari; Luisella Coda; Riccardo Belli; Rita Trinchero
Journal:  Circulation       Date:  2007-05-14       Impact factor: 29.690

Review 8.  Treatment of malignant pericardial effusion.

Authors:  P T Vaitkus; H C Herrmann; M M LeWinter
Journal:  JAMA       Date:  1994-07-06       Impact factor: 56.272

9.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

10.  Malignant pericardial effusion: sclerotherapy or local chemotherapy?

Authors:  C Lestuzzi; C Lafaras; A Bearz; R Gralec; E Viel; A Buonadonna; T Bischiniotis
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more
  3 in total

Review 1.  Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer.

Authors:  Magdalena Zaborowska-Szmit; Maciej Krzakowski; Dariusz M Kowalski; Sebastian Szmit
Journal:  J Clin Med       Date:  2020-04-27       Impact factor: 4.241

2.  Large Pericardial Effusion-Diagnostic and Therapeutic Options, with a Special Attention to the Role of Prolonged Pericardial Fluid Drainage.

Authors:  Małgorzata Dybowska; Monika Szturmowicz; Katarzyna Błasińska; Juliusz Gątarek; Ewa Augustynowicz-Kopeć; Renata Langfort; Paweł Kuca; Witold Tomkowski
Journal:  Diagnostics (Basel)       Date:  2022-06-13

3.  Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin.

Authors:  Sebastian Szmit; Aleksandra Grela-Wojewoda; Małgorzata Talerczyk; Joanna Kufel-Grabowska; Joanna Streb; Jolanta Smok-Kalwat; Dariusz Iżycki; Ewa Chmielowska; Michał Wilk; Barbara Sosnowska-Pasiarska
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.